Question 1 of 6: Small-Diameter Vascular Grafts and Blood-Compatible Surface Strategies

Question 1: Small-Diameter Vascular Grafts and Blood-Compatible Surface Strategies (20 marks)

Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.

(a) Large-bore (>6 mm) Dacron/PTFE grafts succeed because flow in large arteries is fast and highly pulsatile: the resulting wall shear rate is high enough to continuously wash nascent platelet aggregates and fibrin off the luminal surface before they can grow into an occlusive thrombus, and the graft's cross-sectional area is large relative to the thrombogenic surface area presented per unit blood volume. Neither condition holds below about 5–6 mm. Small-diameter grafts see low flow and low wall shear, so platelets have time to adhere, activate, and aggregate on the exposed synthetic surface (Dacron and PTFE have no endothelium and are intrinsically thrombogenic once plasma proteins such as fibrinogen adsorb to them — see part (b)); this satisfies the stasis + surface-contact arms of Virchow's triad and the graft occludes by thrombosis within weeks to months. A second, distinct failure mode is compliance mismatch: synthetic grafts are far stiffer than the native artery they replace, so the anastomosis experiences an abrupt discontinuity in radial compliance under each pulse. The resulting non-physiological wall shear-stress gradients at the suture line drive smooth-muscle-cell proliferation and myointimal (intimal) hyperplasia, which progressively narrows the lumen — a problem that scales inversely with diameter because a fixed hyperplastic thickness removes a much larger fraction of the lumen in a 4 mm graft than in a 8 mm one. Native veins (e.g., the saphenous vein used in coronary and peripheral bypass) avoid both problems: they already carry a functional, anti-thrombotic endothelium and a compliance close to that of the artery they are grafted into.

The engineering challenge is therefore to replicate, in a synthetic or tissue-engineered small-diameter conduit, three properties simultaneously: (i) a durable, confluent, anti-thrombotic luminal lining (ideally a functional endothelium that actively suppresses platelet activation and secretes anticoagulant/vasoactive factors, not merely a "less thrombogenic" polymer); (ii) mechanical compliance matched to the host artery across the full pulse-pressure cycle, without sacrificing burst strength, kink resistance, or long-term durability; and (iii) remodeling into a stable, non-hyperplastic, non-aneurysmal vessel wall rather than a permanent foreign-body interface. These three requirements pull against each other in most current material choices — stiffer wall constructions give burst strength and compliance stability but resist re-endothelialization and remodeling, while compliant biodegradable scaffolds risk aneurysmal dilation before host tissue has taken over the mechanical load. This is, fundamentally, why the goal has not yet been achieved clinically at scale: no single strategy (synthetic tissue-engineered scaffold, decellularized allograft/xenograft, or cell-seeded construct) has yet delivered a functional endothelium and matched compliance and long-term remodeling together in a small-diameter conduit that is also manufacturable and stable in long-term storage, whereas the native vein already provides all three by definition.

(b) Control curve. On the unmodified control surface, adsorbed fibrinogen is highest (≈0.083) at the most dilute plasma tested, drops steeply to ≈0.056 by about 0.5% plasma and to a minimum of ≈0.045 near 5%, and then climbs only slightly (≈0.052 at 20%). This maximum at very low plasma concentration followed by a fall is the signature of the Vroman effect: fibrinogen is one of the most abundant plasma proteins and adsorbs early and strongly, so in dilute plasma, where there is little competition, it accumulates on the bare surface. As plasma concentration (and hence the concentration of every competing protein) increases, lower-abundance but higher-surface-affinity proteins, chiefly the contact-activation proteins high-molecular-weight kininogen and Factor XII, reach the surface in sufficient quantity to displace the initially adsorbed fibrinogen. The amount of fibrinogen left on the surface therefore falls even though more fibrinogen is available in solution. The shallow rise beyond 5% suggests the exchange is essentially complete there, leaving a residual fibrinogen layer that is still substantial. This matters for blood compatibility because surface-adsorbed, denatured fibrinogen exposes a cryptic binding epitope (the γ-chain dodecapeptide) recognized by the platelet integrin GPIIb/IIIa; a surface that retains a substantial adsorbed-fibrinogen layer under physiological (high) plasma concentration is a surface that recruits and activates platelets, triggering the intrinsic coagulation cascade and, ultimately, the thrombotic failure mode described in part (a).

PEO-modified curve. The PEO-modified surface adsorbs far less fibrinogen at every plasma concentration, and its curve has a completely different shape. It starts near ≈0.005 in dilute plasma, about one-sixteenth of the control, and rises slowly and monotonically to ≈0.012 at 5% and ≈0.018 at 20%, with no Vroman maximum. At 20% plasma it still carries only about a third of the control's fibrinogen, a reduction of roughly 65%. The absence of a maximum means there is no early fibrinogen-rich layer being exchanged: what little protein reaches the surface simply accumulates in proportion to how much is in solution. The steady rise also shows that PEO reduces adsorption rather than eliminating it. Proteins still find their way to gaps in chain coverage or compress a sparse brush, so graft density and chain length control how well the coating works, and the benefit should be confirmed at whole-plasma (100%) concentration, beyond the 20% range tested. Grafted polyethylene oxide chains are highly hydrated, flexible, and uncharged; they occupy a large excluded volume at the surface and are entropically unfavourable to compress, so any protein approaching the surface must displace a tightly bound water/PEO layer at a steep free-energy cost (steric-repulsion/hydration-barrier mechanism). The practical significance is that a PEO (or other "stealth"/zwitterionic) coating suppresses the very first step of the surface-thrombosis cascade — protein adsorption — rather than trying to manage its downstream consequences, which is why PEO grafting (and PEGylation generally) became a standard blood-contacting-surface modification strategy.

(c) Native cell membranes, and the red blood cell membrane in particular, present an outer leaflet rich in zwitterionic phospholipids (chiefly phosphatidylcholine). These headgroups carry an equal, closely spaced positive and negative charge, are extremely strongly hydrated, and present essentially no net charge or hydrophobic patch for a plasma protein to bind — which is precisely why a red blood cell can circulate in continuous contact with the coagulation and complement systems for roughly 120 days without itself triggering thrombosis. Grafting phosphorylcholine (PC) head-groups onto a synthetic surface at high density reproduces this same chemistry (and much of the same hydration-barrier physics already described for PEO in part (b)) directly on a polymer or metal substrate. Because the mechanism is biomimetic rather than merely "inert," PC-modified surfaces suppress fibrinogen/complement adsorption and platelet activation through the same evolutionarily validated pathway the body already uses, while offering practical advantages a living cell membrane cannot: PC coatings can be covalently grafted to durable, load-bearing substrates (stent metals, catheter polymers, graft textiles), are stable outside the body during manufacture and storage, and are not subject to the fragility or immunogenicity of a cell-derived coating. This combination — a proven low-fouling biological chemistry delivered on a manufacturable, durable substrate — is why phospholipid-mimetic (MPC-type) coatings are considered a particularly promising route to improved blood-contacting biomaterials, and are already used commercially on coronary stents and extracorporeal circuits.